Decoy Therapeutics Inc.
DCOY
$2.98
-$0.08-2.61%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 227.60K | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 227.60K | -- | -- | -- | -- |
| Cost of Revenue | 1.30M | -- | -- | -- | 116.40K |
| Gross Profit | -1.08M | -- | -- | -- | -116.40K |
| SG&A Expenses | 1.33M | 1.53M | 402.20K | 833.30K | 849.20K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.63M | 2.28M | 516.60K | 895.10K | 965.60K |
| Operating Income | -2.40M | -2.28M | -516.60K | -895.10K | -965.60K |
| Income Before Tax | -2.37M | -2.22M | -8.98M | -873.50K | -957.80K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.37M | -2.22M | -8.98M | -873.50K | -957.80K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.37M | -2.22M | -8.98M | -873.50K | -957.80K |
| EBIT | -2.40M | -2.28M | -516.60K | -895.10K | -965.60K |
| EBITDA | -2.39M | -2.28M | -512.80K | -894.00K | -964.50K |
| EPS Basic | -4.46 | -4.18 | -23.46 | -81.21 | -81.21 |
| Normalized Basic EPS | -2.79 | -2.61 | -0.75 | -- | -50.76 |
| EPS Diluted | -4.46 | -4.18 | -23.46 | -81.21 | -81.21 |
| Normalized Diluted EPS | -2.79 | -2.61 | -0.75 | -- | -50.76 |
| Average Basic Shares Outstanding | 532.00K | 532.00K | 382.70K | -- | 11.80K |
| Average Diluted Shares Outstanding | 532.00K | 532.00K | 382.70K | 11.80K | 11.80K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |